News and Insights

Print this page

Search News & Insights

Matheson advises on the sale of US biotech firm Dyax to UK-listed Shire

AUTHOR(S): Joe Duffy, John Ryan
DATE: 11.11.2015

Matheson advised US biotech firm Dyax on Irish tax matters relating to its US$5.9 billion sale to Shire, the UK-listed pharmaceutical company.  The acquisition is intended to enhance Shire’s position in treating rare genetic diseases.

The deal is expected to close in the first half of 2016.


About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)